SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-033241
Filing Date
2021-03-08
Accepted
2021-03-08 16:01:56
Documents
15
Period of Report
2021-03-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm218840d1_8k.htm   iXBRL 8-K 31327
2 EXHIBIT 99.1 tm218840d1_ex99-1.htm EX-99.1 12226
3 GRAPHIC tm218840d1_ex99-1img01.jpg GRAPHIC 17591
4 GRAPHIC tm218840d1_ex99-1img02.jpg GRAPHIC 13125
  Complete submission text file 0001104659-21-033241.txt   265103

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA casi-20210305.xsd EX-101.SCH 3187
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE casi-20210305_lab.xml EX-101.LAB 34592
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE casi-20210305_pre.xml EX-101.PRE 22711
8 EXTRACTED XBRL INSTANCE DOCUMENT tm218840d1_8k_htm.xml XML 3590
Mailing Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850
Business Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850 240-864-2600
CASI Pharmaceuticals, Inc. (Filer) CIK: 0000895051 (see all company filings)

IRS No.: 581959440 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-20713 | Film No.: 21721899
SIC: 2836 Biological Products, (No Diagnostic Substances)